Erbin as a negative regulator of Ras-Raf-Erk signaling

• US 20040058359A1
• Filed: 05/28/2003
• Published: 03/25/2004
• Est. Priority Date: 05/29/2002
• Status: Abandoned Application

• Current Assignee: UAB Research Foundation (University of Alabama System)
• Original Assignee: UAB Research Foundation (University of Alabama System)
• Inventors: Mei, Lin, Xiong, Wem C., Huang, Yang Z.
• Application Number:
  US10/446,640
• Publication Number:
  US 20040058359A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: A61K 48/005 characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
• CPC Class Codes: C23C 16/4404 Coatings or surface treatment on the inside of the reaction chamber or on parts thereof
• CPC Class Codes: C23C 16/52 Controlling or regulating the coating process C23C16/45557, C23C16/279 take precedence
• CPC Class Codes: G01N 2333/4706 stimulating, promoting or activating activity
• CPC Class Codes: G01N 33/574 for cancer
• CPC Class Codes: H01J 37/32935 Monitoring and controlling tubes by information coming from the object and/or discharge
• CPC Class Codes: H01L 21/67069 for drying etching
• CPC Class Codes: H01L 21/67253 Process monitoring, e.g. flow or thickness monitoring

Abstract

The instant invention provides a method of inhibiting proliferation of maligant cells by administration of a Ras-activity inhibitory effective amount of DNA which encodes the protein Erbin into the maligant cells.

The invention also provides methods for evaluating proliferative properties and progression of proliferative activities in tumor cells by measurement of Erbin in tumor tissue.

Claims

1. A method of inhibiting proliferation of maligant cells by administration of a Ras-activity inhibitory effective amount of DNA which encodes the protein Erbin into the maligant cells.

2. The method of claim 1 wherein the amount of Erbin administered is sufficient to provide an intracellular concentration of 1 μ

M to 100 μ

M of DNA which encodes Erbin into the cells.

3. The method of claim 1 wherein the DNA encoding Erbin is administered via viral vectors.

4. A method of evaluating proliferative properties and progression of proliferative activities in tumor cells by measurement of Erbin in tumor tissue comprising:

1) obtaining tumor tissue or cell lysates and

2) measuring the amount of Erbin in the sample obtained in step 1.

5. The method of claim 4 wherein the amount of Erbin is evaluated by Western blot.

6. The method of claim 4 wherein the amount of Erbin is evaluated by immunohistochemical analysis.